Hereditary transthyretin amyloidosis (hATTR) with polyneuropathy is a rare disease due to mutations in the gene encoding transthyretin (TTR) and characterized by multisystem extracellular deposition of amyloid, leading to dysfunction of different organs and tissues.
AMVUTTRA is the first & only treatment designed with stability in mind to work harder and longer in the body. That's why its given only 4x a year as an injection under the skin. AMVUTTRA quickly helps prevent disease from getting worse. It significantly improves nerve function and quality of life for patients.
Amvuttra
Art Director: Maddie Grube
Copywriter: Matthew Ingardia
Agency: FCB Health
Client: Amvuttra (Alnylam)
Double-Stranded Advantage
People with hATTR amyloidosis have long had to suffer through uncertainty, misdiagnoses, and the constant concern over what to do next. They deserve to know that their treatment is behind them no matter what.
They need more—they need a rally cry, one that empowers them like no other, with the advantage of a double-stranded design proven to improve nerve function and last longer.
For this idea, I pulled inspiration from my art history days, thinking of the flying buttresses of gothic architecture. Flying buttresses act as a sort of exoskeleton, supporting the structure of a building externally while integrating seamlessly into the overall design. AMVUTTRA serves a similar function in patients lives, providing stability (as visualized by the branded double helix. For hATTR patients this means stabilization of their disease progression and symptoms so that they may better st(r)and the test of time.
